MAGEA4抗体;MAGEA4 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using MAGEA4 mouse mAb against Mouse liver (1), Rat liver (2) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of LNCAP cells using MAGEA4 mouse mAb (green) and negative control (red).    

  
  

The MAGE-A4 (Melanoma-Associated Antigen A4) antibody targets a protein belonging to the MAGE family, a group of cancer-testis antigens (CTAs) primarily expressed in germ cells and placental tissues but aberrantly reactivated in various cancers. MAGE-A4 is encoded by the *MAGEA4* gene located on the X chromosome (Xq21.3) and shares homology with other MAGE family members, characterized by a conserved MAGE homology domain (MHD). Its restricted expression in normal tissues and frequent overexpression in malignancies—such as melanoma, lung, ovarian, and hepatocellular carcinomas—make it a promising biomarker and therapeutic target.

MAGE-A4 antibodies are critical tools for detecting this protein in research and diagnostics, aiding in tumor profiling via techniques like immunohistochemistry (IHC) or Western blot. Functionally, MAGE-A4 is implicated in tumorigenesis by modulating ubiquitin ligase activity, apoptosis, and cell cycle regulation, often through interactions with p53 or retinoblastoma (Rb) pathways. Clinically, its expression correlates with tumor aggressiveness and poor prognosis, driving interest in MAGE-A4-targeted immunotherapies. Antibodies enable the study of its role in cancer immunity and support the development of T-cell therapies, vaccines, or antibody-drug conjugates (ADCs). However, challenges remain due to its intracellular localization and variability in tumor-specific expression, necessitating rigorous validation of antibody specificity to avoid cross-reactivity with homologous MAGE proteins.